Investigating Hepatic Fibrosis Heterogeneity by Threedimensional Imaging in Metabolic Dysfunction-Associated Steatotic Liver Disease

Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2025Yazar
Yiğit, BuketÖzgönül, Ekin
Yaman, Ömer
Sipahioğlu, Tarık
Ulukan, Burge
Taş, Yağmur Çetin
Morova, Berna
Aydın, Musa
Uysallı, Yiğit
Demirtaş, Elif
Erkan, Mert
Tellioğlu, Gürkan
Atak, Dila
Özdemir, Yasemin Gürsoy
Karahüseyinoğlu, Serçin
Yurdaydın, Cihan
Akyıldız, Murat
Sheth, Abhishek
Aithal, Guruprasad Padur
Kırımlıoğlu, Hale
Dayangaç, Murat
Ferhanoğlu, Onur
Kiraz, Alper
Zeybel, Müjdat
Üst veri
Tüm öğe kaydını gösterKünye
YİĞİT, Buket, Ekin ÖZGÖNÜL, Ömer YAMAN, Tarık SİPAHİOĞLU, Burge ULUKAN, Yağmur Çetin TAŞ, Berna MOROVA, Musa AYDIN, Yiğit UYSALLI, Elif DEMİRTAŞ, Mert ERKAN, Gürkan TELLİOĞLU, Dila ATAK, Yasemin Gürsoy ÖZDEMİR, Serçin KARAHÜSEYİNOĞLU, Cihan YURDAYDIN, Murat AKYILDIZ, Abhishek SHETH, Guruprasad Padur AİTHAL, Hale KIRIMLIOĞLU, Murat DAYANGAÇ, Onur FERHANOĞLU, Alper KİRAZ & Müjdat ZEYBEL. "Investigating Hepatic Fibrosis Heterogeneity by Threedimensional Imaging in Metabolic Dysfunction-Associated Steatotic Liver Disease". Scientific Reports, 15 (2025): 1-11.Özet
Although liver biopsy is a well-established technique to assess fibrosis it has several limitations,
including invasive nature, semi-quantitative assessment methods, significant sampling and observer
variability, making precise assessment of hepatic fibrosis challenging. Accurate and reliable modalities
are crucial for clinical trials to characterize hepatic fibrosis monitorization effectively. We aimed to
perform 3-dimensional imaging of optically transparent liver samples by light-sheet microscopy (LSM)
to quantify extracellular matrix (ECM) proteins. Fifty-seven MASLD, thirty-eight chronic hepatitis
patients and twelve healthy individuals were included. Liver tissues were cleared with a CLARITY
method. 3D imaging of ECM was performed via the newly developed LSM. Collagen Proportionate
Volume (CPV) and Elastin Proportionate Volume (EPV) values were calculated by analysis of over
200 sections per sample through morphometry. We have optimized a method which achieves
transparency of liver tissues in advanced fibrotic stages of MASLD and optimized non-destructive
slide-free fibrosis pathology of whole fresh and FFPE liver biopsy samples. Cut-off values for CPV and
EPV were established for fibrotic stages. CPV and EPV analysis showed a considerable optical section
heterogeneity resulting in a fibrosis stage of variance within the sample. Volumetric image analysis
for fibrosis staging revealed that only 44% and 47% of optical sections would be staged the same for
F3 and F4, respectively. For the first time, our findings demonstrate a novel method of analyzing 3D
digital pathology of liver fibrosis using in-house LSM. Volumetric imaging of whole liver biopsy samples
showed that fibrosis heterogeneity occurs even in different sections.


















